Search Results - "Petty, Kevin J."

Molecular profiling and gene expression analysis in cutaneous sarcoidosis: The role of interleukin-12, interleukin-23, and the T-helper 17 pathway by Judson, Marc A., MD, Marchell, Richard M., MD, Mascelli, MaryAnn, PhD, Piantone, Alexa, PharmD, Barnathan, Elliot S., MD, Petty, Kevin J., MD, Chen, Dion, PhD, Fan, Hongtao, PhD, Grund, Heidi, RN, Ma, Keying, PhD, Baribaud, Frédéric, PhD, Brodmerkel, Carrie, PhD

“…Background Cutaneous sarcoidosis (CS) skin provides relatively noninvasive access to granulomatous sarcoidosis tissue. Objective We sought to explore the role…”
Get full text

Golimumab Pharmacokinetics After Repeated Subcutaneous and Intravenous Administrations in Patients with Rheumatoid Arthritis and the Effect of Concomitant Methotrexate: An Open-Label, Randomized Study by Zhuang, Yanli, PhD, Xu, Zhenhua, PhD, FCP, Frederick, Bart, BS, de Vries, Dick E., MD, Ford, Joyce A., MS, Keen, Monica, BS, Doyle, Mittie K., MD, Petty, Kevin J., MD, PhD, Davis, Hugh M., PhD, Zhou, Honghui, PhD, FCP

“…Abstract Background The pharmacokinetics of golimumab, a human monoclonal antibody that inhibits the activity of tumor necrosis factor α, after a single…”
Get full text

Safety, tolerability and pharmacokinetics of a human anti‐interleukin‐13 monoclonal antibody (CNTO 5825) in an ascending single‐dose first‐in‐human study by Hartingsveldt, Bart, Nnane, Ivo P., Bouman‐Thio, Esther, Loza, Matthew J., Piantone, Alexa, Davis, Hugh M., Petty, Kevin J.

“…Aims To assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of CNTO 5825 following single‐dose intravenous (i.v.)…”
Get full text

Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant by Bergström, Mats, Hargreaves, Richard J, Burns, H.Donald, Goldberg, Michael R, Sciberras, David, Reines, Scott A, Petty, Kevin J, Ögren, Mattias, Antoni, Gunnar, Långström, Bengt, Eskola, Olli, Scheinin, Mika, Solin, Olof, Majumdar, Anup K, Constanzer, Marvin L, Battisti, Wendy P, Bradstreet, Thomas E, Gargano, Cynthia, Hietala, Jarmo

“…Aprepitant is a highly selective substance P (neurokinin 1 [NK 1] receptor) antagonist that significantly improves the pharmacotherapy of acute and delayed…”
Get full text

Comparison of the Pharmacokinetics of Subcutaneous Ustekinumab between Chinese and Non-Chinese Healthy Male Subjects across Two Phase 1 Studies by Zhu, Yaowei, Wang, Qingmin, Frederick, Bart, Bouman-Thio, Esther, Marini, Joseph C., Keen, Monica, Petty, Kevin J., Davis, Hugh M., Zhou, Honghui

“…Background and Objective Ustekinumab, a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody against interleukin-12/23p40, has been reported to be…”
Get full text

Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity by Shadle, Craig R., Lee, Yih, Majumdar, Anup K., Petty, Kevin J., Gargano, Cynthia, Bradstreet, Thomas E., Evans, Judith K., Blum, Robert A.

“…The NK1 receptor antagonist aprepitant (EMEND®), developed for use in combination with a 5HT3 receptor antagonist and a corticosteroid to prevent highly…”
Get full text

Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers by Majumdar, Anup K., Howard, Laura, Goldberg, Michael R., Hickey, Lisa, Constanzer, Marvin, Rothenberg, Paul L., Crumley, Tami M., Panebianco, Deborah, Bradstreet, Thomas E., Bergman, Arthur J., Waldman, Scott A., Greenberg, Howard E., Butler, Kathleen, Knops, A., De Lepeleire, Inge, Michiels, Nicole, Petty, Kevin J.

“…Aprepitant is the first NK1 receptor antagonist approved for use with corticosteroids and 5HT3 receptor antagonists to prevent chemotherapy‐induced nausea and…”
Get full text

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients by NYGREN, Peter, HANDE, Kenneth, GOTTESDIENER, Keith M, COCQUYT, Veronique, VAN BELLE, Simon, PETTY, Kevin J, FEDGCHIN, Margaret, VAN DYCK, Kristien, MAJUMDAR, Anup, PANEBIANCO, Debbie, DE SMET, Marina, AHMED, Tuli, MURPHY, M. Gail

“…Aprepitant is a selective neurokinin-1 receptor antagonist that is effective for the prevention of nausea and vomiting caused by highly emetogenic…”
Get full text

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects by Blum, Robert A., Majumdar, Anup, McCrea, Jacqueline, Busillo, John, Orlowski, Laura H., Panebianco, Deborah, Hesney, Michael, Petty, Kevin J., Goldberg, Michael R., Murphy, M.Gail, Gottesdiener, Kevin M., Hustad, Carolyn M., Lates, Christian, Kraft, Walter K., Van Buren, Sandi, Waldman, Scott A., Greenberg, Howard E.

“…Background: The neurokinin-1-receptor antagonist aprepitant, when given in combination with a corticosteroid and a 5-hydroxytryptamine type 3 (5-HT 3)-receptor…”
Get full text

Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant by BERGMAN, Arthur J, MARBURY, Thomas, HUSKEY, Su-Er W, MAJUMDAR, Anup, FOSBINDER, Trisha, SWAN, Suzanne, HICKEY, Lisa, BRADSTREET, Thomas E, BUSILLO, John, PETTY, Kevin J, AIYER, Kala-Jyoti Viswanathan, CONSTANZER, Marvin

“…The neurokinin NK(1)-receptor antagonist aprepitant has demonstrated efficacy in preventing highly emetogenic chemotherapy-induced nausea and vomiting. The…”
Get full text

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone by McCrea, Jacqueline B., Majumdar, Anup K., Goldberg, Michael R., Iwamoto, Marian, Gargano, Cynthia, Panebianco, Deborah L., Hesney, Michael, Lines, Christopher R., Petty, Kevin J., Deutsch, Paul J., Murphy, M. Gail, Gottesdiener, Keith M., Goldwater, D. Ronald, Blum, Robert A.

“…Background Aprepitant is a neurokinin1 receptor antagonist that, in combination with a corticosteroid and a 5‐hydroxytryptamine3 receptor antagonist, has been…”
Get full text

Pharmacokinetics and Safety of Golimumab in Healthy Chinese Subjects Following a Single Subcutaneous Administration in a Randomized Phase I Trial by Zhuang, Yanli, Lyn, Sally, Lv, Yuan, Xu, Zhenhua, Bouman-Thio, Esther, Masterson, Tara, Ford, Joyce A., Keen, Monica, Petty, Kevin J., Davis, Hugh M., Zhou, Honghui

“…Background and Objectives Golimumab is an anti-tumor necrosis factor-α human immunoglobulin G1 κ monoclonal antibody that is efficacious for the treatment of…”
Get full text

Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects by YANLI ZHUANG, ZHENHUA XU, PETTY, Kevin J, DAVIS, Hugh M, HONGHUI ZHOU, DE VRIES, Dick E, QINGMIN WANG, SHISHIDO, Akira, COMISAR, Craig, FORD, Joyce A, KEEN, Monica, ACHIRA, Meguru, TSUKAMOTO, Yuko

“…Sirukumab (CNTO 136) is a human mAb with high affinity and specificity for binding to interleukin-6. This Phase 1 study evaluated the pharmacokinetics,…”
Get full text

Placebo- and Amitriptyline-Controlled Evaluation of Central Nervous System Effects of the NK1 Receptor Antagonist Aprepitant and Intravenous Alcohol Infusion at Pseudo-Steady State by te Beek, Erik T., Tatosian, Daniel, Majumdar, Anup, Selverian, Diana, Klaassen, Erica S., Petty, Kevin J., Gargano, Cynthia, van Dyck, Kristien, McCrea, Jacqueline, Murphy, Gail, van Gerven, Joop M.A.

“…Recent interest in NK1 receptor antagonists has focused on a potential role in the treatment of drug addiction and substance abuse. In the present study, the…”
Get full text

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe by Majumdar, Anup K., McCrea, Jacqueline B., Panebianco, Deborah L., Hesney, Michael, Dru, James, Constanzer, Marvin, Goldberg, Michael R., Murphy, Gail, Gottesdiener, Keith M., Lines, Christopher R., Petty, Kevin J., Blum, Robert A.

“…Background Aprepitant is a neurokinin1 receptor antagonist that enhances prevention of chemotherapy‐induced nausea and vomiting when added to conventional…”
Get full text

Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant by Stoch, S. Aubrey, Gargano, Cynthia, Valentine, Jack, Braun, Matthew P., Murphy, M. Gail, Fedgchin, Margaret, Majumdar, Anup, Pequignot, Edward, Gottesdiener, Keith M., Petty, Kevin J., Panebianco, Deborah, Dean, Dennis, Kraft, Walter K., Greenberg, Howard E.

“…Purpose Because glucocorticoids and the neurokinin-1 receptor antagonist aprepitant influence CYP3A4 activity, this study assessed whether aprepitant added to…”
Get full text

Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam by Majumdar, Anup K., Yan, Kerri X., Selverian, Diana V., Barlas, Suna, Constanzer, Marvin, Dru, James, McCrea, Jacqueline B., Ahmed, Tuli, Frick, Glen S., Kraft, Walter K., Petty, Kevin J., Greenberg, Howard E.

“…Oral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in…”
Get full text

Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers by Li, Susie Xiujiang, Pequignot, Edward, Panebianco, Deborah, Lupinacci, Paul, Majumdar, Anup, Rosen, Laura, Ahmed, Tuli, Royalty, Jane E., Rushmore, Thomas H., Murphy, M. Gail, Petty, Kevin J.

“…To prevent chemotherapy‐induced nausea and vomiting, aprepitant is given with a corticosteroid and a 5‐hydroxytryptamine type 3 antagonist, such as dolasetron…”
Get full text

Lack of Effect of Aprepitant on Digoxin Pharmacokinetics in Healthy Subjects by Feuring, Martin, Lee, Yih, Orlowski, Laura H., Michiels, Nicole, De Smet, Marina, Majumdar, Anup K., Petty, Kevin J., Goldberg, Michael R., Murphy, M. Gail, Gottesdiener, Keith M., Hesney, Michael, Brackett, L. Ellen, Wehling, Martin

“…Aprepitant is a highly selective neurokinin‐1 receptor antagonist that, in combination with a corticosteroid and a 5‐hydroxytryptamine3 (5HT3) receptor…”
Get full text

Pharmacokinetics of Etoricoxib in Patients with Hepatic Impairment by Agrawal, Nancy G. B., Rose, Mark J., Matthews, Catherine Z., Woolf, Eric J., Porras, Arturo G., Geer, Leslie A., Larson, Patrick J., Cote, Josee, Dilzer, Stacy C., Lasseter, Kenneth C., Alam, Imtiaz, Petty, Kevin J., Gottesdiener, Keith M.

“…The effect of hepatic insufficiency on the pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase‐2, was investigated following administration…”
Get full text